Molecular determinants of biased agonism at the dopamine D₂ receptor.

The development of biased (functionally selective) ligands provides a formidable challenge in medicinal chemistry. In an effort to learn to design functionally selective molecular tools for the highly therapeutically relevant dopamine D2 receptor, we synthesized a collection of agonists based on structurally distinct head groups derived from canonical or atypical dopaminergic pharmacophores. The test compounds feature a long lipophilic appendage that was shown to mediate biased signaling. By employing functional assays and molecular dynamics simulations, we could show that atypical dopamine surrogates of type 1 and 2 promote biased signaling, while ligands built from classical dopaminergic head groups (type 3 and 4) typically elicit more balanced signaling profiles. Besides this, we found a strong influence of the stereochemistry of type 4 aminotetraline-derived agonists on functional selectivity at D2 receptors. Whereas the (S)-enantiomer behaved as a full agonist, the biased ligand (R)-4 induced poor G protein coupling but substantial β-arrestin recruitment.

[1]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[2]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[3]  Hualiang Jiang,et al.  Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.

[4]  J. Hieble,et al.  Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives. , 1985, Journal of medicinal chemistry.

[5]  P. Gmeiner,et al.  Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.

[6]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[7]  B. Mckittrick,et al.  Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery. , 2014, Journal of medicinal chemistry.

[8]  M. Fishman,et al.  Activated mutants of the alpha subunit of G(o) promote an increased number of neurites per cell , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  S. Hjorth,et al.  Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.

[10]  Eric Trinquet,et al.  Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy , 2012, Proceedings of the National Academy of Sciences.

[11]  H. Nakata,et al.  Functional Characterization of Gαo Signaling through G Protein-Regulated Inducer of Neurite Outgrowth 1 , 2005, Molecular Pharmacology.

[12]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[13]  A. Christopoulos,et al.  A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.

[14]  R. A. Moyer,et al.  An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization , 2007, Molecular Pharmacology.

[15]  R. Lefkowitz,et al.  When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.

[16]  Maria F. Sassano,et al.  Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. , 2012, Journal of medicinal chemistry.

[17]  R. Baldessarini,et al.  Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. , 2013, Chemical reviews.

[18]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[19]  P. Gmeiner,et al.  Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. , 2008, Journal of medicinal chemistry.

[20]  Olivier Lichtarge,et al.  β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor* , 2006, Journal of Biological Chemistry.

[21]  H. V. Van Tol,et al.  Modulation of Intracellular Cyclic AMP Levels by Different Human Dopamine D4 Receptor Variants , 1995, Journal of neurochemistry.

[22]  S. Nickolls,et al.  Functional coupling of the human dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins: evidence for agonist regulation of G protein selectivity , 2003 .

[23]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[24]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[25]  Arthur Christopoulos,et al.  Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.

[26]  Christopher G. Tate,et al.  Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.

[27]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[28]  F. Boeckler,et al.  Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.

[29]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[30]  P. Gmeiner,et al.  Development of a bivalent dopamine D₂ receptor agonist. , 2011, Journal of medicinal chemistry.

[31]  H. Jensen,et al.  Microwave Irradiation as anEffective Means of Synthesizing Unsubstituted N-Linked 1,2,3-Triazolesfrom Vinyl Acetate and Azides , 2009 .

[32]  J. Cannon Structure-activity relationships of dopamine agonists. , 1983, Annual review of pharmacology and toxicology.

[33]  K. Neve Functional selectivity of G protein-coupled receptor ligands : new opportunities for drug discovery , 2009 .

[34]  Cheng Zhang,et al.  Irreversible Agonist-Beta2 Adrenoceptor Complex , 2011 .

[35]  F. Wurm,et al.  Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. , 1996, Nucleic acids research.

[36]  M. Sodeoka,et al.  A New Route for the Preparationof Succinates , 2008 .

[37]  Lisa Nguyen,et al.  Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.

[38]  Ralf C. Kling,et al.  Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. , 2013, Journal of medicinal chemistry.

[39]  S. Rees,et al.  Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. , 1997, The Biochemical journal.

[40]  Susana R. Neves,et al.  G Protein-regulated Inducer of Neurite Outgrowth (GRIN) Modulates Sprouty Protein Repression of Mitogen-activated Protein Kinase (MAPK) Activation by Growth Factor Stimulation* , 2012, The Journal of Biological Chemistry.

[41]  Ravi Iyengar,et al.  Regulation of neurite outgrowth by G(i/o) signaling pathways. , 2008, Frontiers in bioscience : a journal and virtual library.

[42]  R. Gainetdinov,et al.  Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.

[43]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[44]  P. Gmeiner,et al.  Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. , 2011, Journal of medicinal chemistry.

[45]  S. Senogles The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. , 1994, The Journal of biological chemistry.

[46]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[47]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[48]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[49]  Kurt Wüthrich,et al.  Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.

[50]  Ralf C. Kling,et al.  Functionally selective dopamine D₂, D₃ receptor partial agonists. , 2014, Journal of medicinal chemistry.

[51]  Maarten G. Wolf,et al.  g_membed: Efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation , 2010, J. Comput. Chem..

[52]  P. Gmeiner,et al.  Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.

[53]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[54]  P. Greengard,et al.  Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Christopoulos,et al.  Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.

[56]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[57]  Maria F. Sassano,et al.  Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy , 2011, Proceedings of the National Academy of Sciences.

[58]  Peter Gmeiner,et al.  Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor. , 2011, Journal of molecular biology.

[59]  T. Kenakin,et al.  Measurements of ligand bias and functional affinity , 2013, Nature Reviews Drug Discovery.

[60]  L. Naylor,et al.  Effect of Multiple Serine/Alanine Mutations in the Transmembrane Spanning Region V of the D2 Dopamine Receptor on Ligand Binding , 2000, Journal of neurochemistry.

[61]  E. Davidov,et al.  New Derivatives of L-Glutamine† , 1969 .

[62]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[63]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[64]  K. Neve,et al.  Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. , 1998, Molecular pharmacology.

[65]  T. Biden,et al.  Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. , 1992, Molecular Endocrinology.

[66]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.